You don’t have any Active Subscription.
Subscribed with another email? Logout and Login with that one.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription
Weather News October 31, 2026 e-Paper
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Updated - September 27, 2022 08:39 pm IST - CHENNAI
A view of the Torrent Pharmaceuticals Research Centre. Photo taken from torrentpharma.com
Torrent Pharmaceuticals Ltd. will buy 100% of Curatio Healthcare (I) Pvt. Ltd. for ₹2,000 crore to strengthen its presence in the fast-growing dermatology segment.
The consideration includes ₹115 crore in cash and cash equivalents in the acquired business, indicating an enterprise value of ₹1,885 crore, Torrent Pharmaceuticals said in a release. Curatio Healthcare has operations in India, Nepal, Sri Lanka and Philippines.
In the cosmetic dermatology segment, Curatio has a portfolio of more than 50 brands, including brands such as Tedibar, Atogla, Spoo, B4 Nappi, and Permite, which are ranked among the top five brands in their covered markets, Torrent Pharmaceuticals said in an investor presentation.
Top ten brands of Curatio account for 74% of total revenue and top 3 brands about 50% of total sales. Cosmetic dermatology accounts for 84% of revenue.
Curatio posted a revenue of ₹224 crore for FY22. With YTD August sales up by 25%, it is expected to cross ₹275 crore in FY23.
With this deal, Torrent Pharmaceuticals would enter the league of top 10 players in the dermatology segment from the current 21 st position, Torrent Pharmaceuticals said in the release.
Commenting on the acquisition, Aman Mehta, Director said “We are delighted to enter into this deal with Curatio. The acquisition offers Torrent the opportunity to enhance its presence in dermatology with a differentiated portfolio and is a strong strategic fit. Curatio has built a commendable set of high market share brands in cosmetic and pediatric dermatology that we look forward to adding to our product offerings.”
Published - September 27, 2022 08:16 pm IST
Copyright© 2026, THG PUBLISHING PVT LTD. or its affiliated companies. All rights reserved.
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
Loading comments…